Every material Form 8-K MAXCYTE, INC. has filed with the SEC since June 16, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
MaxCyte reported preliminary, unaudited third quarter 2026 core business revenue of approximately $8.1 million, up 26% from the third quarter of 2025, and raised its full-year 2026 revenue guidance to approximately $34 million from $30 million to $32 million. The company said the results are subject to change and not audited, but described third quarter and second half revenue as ahead of its expectations, driven by accelerated instrument purchasing from a large customer and a milestone from an SPL partner.
Preliminary Q3 2026 core business revenue of approximately $8.1 million, up 26% year over year; SPL Program-related revenue of more than $1.0 million, including $1.0 million in milestone revenue.
Full-year 2026 revenue guidance raised to approximately $34 million from $30 million to $32 million.
Core business revenue guidance raised to approximately $28 million from $25 million to $27 million; SPL Program-related guidance raised to approximately $6 million from approximately $5 million.
Results are unaudited and subject to change; full third quarter results and royalty revenue will be reported on November 10, 2026.
MaxCyte reported second-quarter 2026 revenue of $7.3 million, down 15% from a year earlier, while its net loss narrowed to $8.9 million from $12.4 million. The company reiterated full-year 2026 revenue guidance of $30 million to $32 million, so shareholders get a smaller loss alongside a shrinking top line.
Total revenue $7.3 million vs. $8.5 million in Q2 2025, down 15%; core revenue down 21% to $6.5 million
Net loss $8.9 million vs. $12.4 million a year earlier; operating expenses $15.8 million vs. $21.2 million
Full-year 2026 revenue guidance of $30 million to $32 million reiterated; year-end cash expected to be at least $130.5 million
Repurchased about $5.5 million of common stock to date under a $10 million buyback; cash and investments $141.9 million at June 30, 2026
MaxCyte received a Nasdaq letter on June 10, 2026 stating that its common stock closed at $1.00 or above for the last 10 consecutive business days, from May 27 to June 9, 2026. Nasdaq closed the matter, and the company says it has regained compliance with the minimum bid price rule. This removes the bid price deficiency that Nasdaq had flagged in March 2026.
Nasdaq notice on March 16, 2026 cited a closing bid price below $1.00 for 30 consecutive trading days
Nasdaq letter dated June 10, 2026 confirmed the closing bid price was at $1.00 or greater from May 27 to June 9, 2026
Nasdaq closed the matter under Listing Rule 5450(a)(1)
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every MAXCYTE, INC. filing is on SEC EDGAR ↗. 8-K briefs of other companies →